CorMedix Reaffirms FY26 Revenue Guidance at $300M-$320M
CRMD sits 20% above its 52-week low of $5.6.
Summary
CorMedix Inc. has reaffirmed its revenue guidance for fiscal year 2026, projecting sales to be between $300 million and $320 million. This confirmation provides a key financial outlook for the company, establishing expectations for its future performance. For a company of CorMedix's size, this revenue range is a material forward-looking statement that traders will integrate into their valuation models and growth assessments. Investors will now focus on the company's ability to execute against these targets and any upcoming catalysts that could impact these projections.
At the time of this announcement, CRMD was trading at $6.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $561M. The 52-week trading range was $5.60 to $17.43. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.